Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.

J Clin OncolJul 13, 2026 (epub)
Clinical ResearchOncology (Medical)

Jamie L Lesnock, Sarah Temin, Sara Bouberhan et al.

✦ AI-curated · Sources linked

In 30 seconds

The ASCO Living Guideline provides updated recommendations for the systemic treatment of recurrent high-grade serous and/or endometrioid epithelial ovarian cancer. A systematic review of 819 publications identified 147 relevant studies, with 36 directly informing the guidelines. For platinum-sensitive cases, platinum-based combinations are recommended, while mirvetuximab soravtansine is strongly recommended for platinum-resistant cases with validated folate receptor alpha expression.

Key findings

  • For recurrent platinum-sensitive EOC, platinum-based combinations like PLD plus carboplatin are recommended.
  • Mirvetuximab soravtansine is strongly recommended for platinum-resistant EOC with validated FRα expression.
  • Secondary cytoreduction may be discussed for platinum-sensitive recurrences with achievable complete resection.

Why it matters

These guidelines synthesize current evidence to inform clinical decision-making in the management of recurrent ovarian cancer, ensuring that patients receive the most effective systemic therapies based on their disease characteristics.

Source

PubMed · PMID 42441925

Published in J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.